On behalf of the Diabetes Incidence after Renal Transplantation: Neoral® C2 monitoring versus Tacrolimus (DIRECT) investigators (see Acknowledgments)
1600-6143/asset/olbannerleft.gif?v=1&s=c46a3f174bfd9c6eb548cc809401524372c32e90)
1600-6143/asset/olbannerright.gif?v=1&s=9fc9790fa8ad5ef85aeaf408bf0d3d969d2fc012)
Original Article
You have full text access to this OnlineOpen article
Polyomavirus BK Replication in De Novo Kidney Transplant Patients Receiving Tacrolimus or Cyclosporine: A Prospective, Randomized, Multicenter Study
Article first published online: 8 NOV 2012
DOI: 10.1111/j.1600-6143.2012.04320.x
© Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons
Additional Information
How to Cite
Hirsch, H. H., Vincenti, F., Friman, S., Tuncer, M., Citterio, F., Wiecek, A., Scheuermann, E. H., Klinger, M., Russ, G., Pescovitz, M. D. and Prestele, H. (2013), Polyomavirus BK Replication in De Novo Kidney Transplant Patients Receiving Tacrolimus or Cyclosporine: A Prospective, Randomized, Multicenter Study. American Journal of Transplantation, 13: 136–145. doi: 10.1111/j.1600-6143.2012.04320.x
- †
On behalf of the Diabetes Incidence after Renal Transplantation: Neoral® C2 monitoring versus Tacrolimus (DIRECT) investigators (see Acknowledgments)
Publication History
- Issue published online: 26 DEC 2012
- Article first published online: 8 NOV 2012
- Manuscript Revised: 6 SEP 2012
- Manuscript Received: 21 MAY 2012
Funded by
- Novartis Pharma
References
- 1, , , et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67: 103–109.
- 2, , , et al. Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 1999; 67: 918–922.
- 3, , , . The decade of polyomavirus BK-associated nephropathy: State of affairs. Transplantation 2009; 87: 621–630.
- 4, , , et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13: 2145–2151.
- 5, , , et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplantation 2005; 79: 1277–1286.
- 6, , , et al. Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 2006; 6(5 Pt 1): 1025–1032.
- 7, , . An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation. 2009; 87: 1019–1026.
- 8, , , , , . Treatment for BK virus: Incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22: 626–634.
- 9, , , et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347: 488–496.
- 10, , , et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342: 1309–1315.
- 11, , , et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5: 582–594.
- 12, , , et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 2007; 84: 340–345.
- 13, , , et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7: 2727–2735.
- 14, , , et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010; 10: 2615–2623.
- 15, , , et al. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9(Suppl 3): S1–S155.
- 16, . BK virus in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S136–S146.
- 17, .Polyomavirus BK. Lancet Infect Dis 2003; 3: 611–623.
- 18, , , et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009; 199: 837–846.
- 19, , , et al. Immunosuppression: Evolution in practice and trends, 1994–2004. Am J Transplant 2006; 6(5 Pt 2): 1111–1131.
- 20, , , et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: A case–control study. Transplantation 2009; 88: 83–88.
- 21
- 22, , , et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506–1514.
- 23, , . Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 2001; 184: 1494–1495; author reply 5–6.
- 24, , , , . Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant 2008; 8: 2368–2377.
- 25, , , et al. Epidemiology of BK virus in renal allograft recipients: Independent risk factors for BK virus replication. Transplantation 2008; 86: 521–528.
- 26, , , et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008; 205: 841–852.
- 27, , , et al. Polyomavirus-associated nephropathy risk in kidney transplants: The influence of recipient age and donor gender. Kidney Int 2007; 71: 1302–1309.
- 28, , , et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005; 19: 199–206.
- 29, , , et al. Prospective monitoring of BK virus replication in renal transplant recipients. Transpl Infect Dis 2009; 11: 1–10.
- 30, , . Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis 2006; 193: 80–87.
- 31, , , et al. A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation 2010; 89: 299–306.
- 32, , , . In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis 2008; 10: 385–390.
- 33, , . Suppression of early and chronic BK polyoma virus replication by mycophenolic acid in Vero cells. Transpl Int 2009; 22: 225–231.
- 34, , . Polyomavirus BK (BKV) replication in renal tubular epithelial cells is inhibited by mTOR inhibitors, but activated by tacrolimus in a pathway involving the FKBP12 (Abstract #497; Accepted for Oral Presentation at the 11th ATC 2011). Am J Transplant 2011; 11–179.
- 35, . Infection in organ-transplant recipients. N Engl J Med. 1998; 338: 1741–1751.
- 36, , . Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008; 13: 569–574.